COVID-19  •  Actus des entreprises Santé - médical - pharmaceutique

Avertim | Covid-19 tracker - Status of the Top 5 vaccines candidates

Avertim is an Innovation and Management consulting group dedicated to building the bridge between Strategy and Operations. Our mission is to translate client’s strategy into actionable projects and enable Business, Technology and Management alignment. 

Avertim has a vast experience in the pharmaceutical and especially the vaccines industry. Therefore, we are closely watching the development of COVID-19 candidates and working with some of the leading companies to plan activities such as manufacture ramp-ups. In this article, find out more about the latest development of the most advanced vaccine projects, often lead by partnerships of leading pharmaceutical development and manufacturing companies.

Over 230 vaccines
The WHO tracks the global research efforts against COVID-19 and continuously reports on their progress. As of March 2021, there are more than 260 vaccines against COVID-19 in different stages of pre-clinical and clinical development (see Figure 1). Scientists and companies are currently testing 63 vaccines in clinical trials (Phase I, II and III) and although some vaccines have received emergency use authorization, no vaccine was fully approved yet.  

What’s new?
The world is still worried by the emerging coronavirus variants, especially the ones from the UK and South Africa who both appear to be more contagious. The South African and UK variant show multiple changes in the spike protein. This protein enables the virus to enter, thus infect, human cells. These changes have not altered the spike protein shape and ongoing studies aim to confirm the effectiveness of the current vaccines. Moreover, a new coronavirus variant, discovered and currently spreading in California appears to be more contagious than previous variants This strain produces double the amount of viral particles and might be more resistant to the approved vaccines.

In addition, vaccine producers struggle to manufacture and deliver enough vaccines around the world. More and more pharma companies are combining their efforts to support the manufacturing.


To read the full article check out our website:

Feel free to connect and follow our journey!

For more information, please contact : Thomas Sieburgh


                                      Website                                                         LinkedIn

Partager cette page Partager sur TwitterPartager sur Linkedin

Newsletter Cap sur les Pays-Bas

Toutes les informations indispensables pour votre développement aux Pays-Bas !